Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 337 followers
Latest posts
Last updated about 14 hours ago
Clinical trial flaws ‘being scaled, not solved’ by AI: report
about 14 hours ago
Clinical trial data company Phesi’s new analysis found that fewer than one...
Facing mounting China licensing costs, biopharma buyers turn to AI and local know-how to keep up
about 14 hours ago
Chinese companies now represent 50% of global out-licensing deals, with U.S. companies...
Incyte inks deal with Edison Scientific to train AI through drug discovery
about 15 hours ago
Incyte and Edison Scientific have signed a collaboration to employ Edison’s AI...
Merck inks Keytruda supply pact to support Exelixis’ colorectal cancer trial
about 15 hours ago
Exelixis has secured supplies of subcutaneous Keytruda from Merck & Co. for...
Lauxera Capital Partners raises a hefty €520M for health, medtech companies
about 17 hours ago
Lauxera Capital Partners has nearly doubled the size of its first funding...
Herantis taps Indivi for digital biomarker tech in Parkinson’s disease trial
about 18 hours ago
Finnish biotech Herantis Pharma is teaming up with Swiss medtech Indivi to...
Relay ‘full steam ahead’ on PI3K inhibitor fueled by first phase 2 data in blood vessel disorder
about 19 hours ago
Relay Therapeutics’ R&D chief remains convinced the biotech’s PI3Kα inhibitor will carve...
Sanofi and Wave post AATD updates in race to end genetic disease’s 40-year new treatment drought
1 day ago
Sanofi and Wave Life Sciences are using their time at the annual...
Vincetage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators
1 day ago
Vincentage Pharma’s oral GLP-1 agonist has been tied to mean weight loss...
BioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal
1 day ago
BioMarin’s $270 million bet on Inozyme’s enzyme replacement therapy looks in trouble...
After rare disease flop, cash-strapped Quince finds salvation in reverse merger
1 day ago
After launching a hunt for strategic alternatives in January following a phase...
Nominations now open for Fierce Biotech's 2026 Fierce 15
1 day ago
It's time to kick off our annual hunt for the latest crop...